[1] |
郭陟永, 刘济远, 李春洁, 等. 药物相关性颌骨坏死发病机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(6): 717-724.
|
[2] |
苏程, 王泽坤, 骆南羽, 等. 药物相关性颌骨坏死的研究进展[J]. 国际口腔医学杂志, 2017, 44(2): 228-234.
|
[3] |
王杞章, 刘济远, 潘剑. 药物性颌骨坏死的研究进展[J]. 华西口腔医学杂志, 2018, 36(5): 568-572.
|
[4] |
沈亚俊, 关键, 葛成. 药物相关性颌骨坏死的研究进展[J]. 中华老年口腔医学杂志, 2016, 14(4): 242-247.
|
[5] |
Vescovi P, Merigo E, Meleti M, et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw[J]. Int J Dent, 2014, 2014: 107690.
|
[6] |
Rugani P, Acham S, Kirnbauer B, et al. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series[J]. Clin Oral Investig, 2015, 19(6): 1329-1338.
doi: 10.1007/s00784-014-1384-1
URL
|
[7] |
Giner M, Vázquez-Gámez MA, Miranda MJ, et al. Circulating osteogenic progenitor cells enhanced with teriparatide or denosumab treatment[J]. J Clin Med, 2022, 11(16): 4749.
doi: 10.3390/jcm11164749
URL
|
[8] |
Collinge C, Favela J. Use of teriparatide in osteoporotic fracture patients[J]. Injury, 2016, 47(Suppl 1): S36-S38.
|
[9] |
Zandi M, Dehghan A, Amini P, et al. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw[J]. Clin Oral Investig, 2019, 23(11): 3987-3993.
doi: 10.1007/s00784-019-02830-2
|
[10] |
李庆帆, 王佐林. ALP、Runx2及OCN在大鼠拔牙后牙槽骨来源BMSCs中的表达[J]. 口腔颌面外科杂志, 2017, 27(02): 77-82.
|
[11] |
Howie RN, Borke JL, Kurago Z, et al. A model for osteonecrosis of the jaw with zoledronate treatment following repeated major trauma[J]. PLoS One, 2015, 10(7): e0132520.
doi: 10.1371/journal.pone.0132520
URL
|
[12] |
Biasotto M, Chiandussi S, Zacchigna S, et al. A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw[J]. J Oral Pathol Med, 2010, 39(5): 390-396.
doi: 10.1111/j.1600-0714.2009.00878.x
pmid: 20202091
|
[13] |
Yang HW, Pan H, Yu F, et al. A novel model of bisphosphonate-related osteonecrosis of the jaw in rats[J]. Int J Clin Exp Pathol, 2015, 8(5): 5161-5167.
|
[14] |
Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase Ⅲ trials in cancer patients with bone metastases[J]. Ann Oncol, 2012, 23(5): 1341-1347.
doi: S0923-7534(19)34695-2
pmid: 32018598
|
[15] |
罗晨, 赵燕平, 马绪臣. 25例双膦酸盐相关颌骨坏死病例分析[J]. 现代口腔医学杂志, 2015, 29(2): 84-90.
|
[16] |
Ali-Erdem M, Burak-Cankaya A, Cemil-Isler S, et al. Extraction socket healing in rats treated with bisphosphonate: Animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients[J]. Med Oral Patol Oral Cir Bucal, 2011, 16(7): e879-e883.
|
[17] |
Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis[J]. Drugs, 2011, 71(6): 791-814.
doi: 10.2165/11585470-000000000-00000
pmid: 21504254
|
[18] |
Maahs MP, Azambuja AA, Campos MM, et al. Association between bisphosphonates and jaw osteonecrosis: A study in Wistar rats[J]. Head Neck, 2011, 33(2): 199-207.
doi: 10.1002/hed.v33.2
URL
|
[19] |
Meganck JA, Begun DL, McElderry JD, et al. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta[J]. Bone, 2013, 56(1): 204-212.
doi: 10.1016/j.bone.2013.06.003
pmid: 23774443
|
[20] |
Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate[J]. J Bone Miner Res, 2004, 19(11): 1779-1786.
doi: 10.1359/JBMR.040814
pmid: 15476577
|
[21] |
Li C, Mori S, Li J, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats[J]. J Bone Miner Res, 2001, 16(3): 429-436.
doi: 10.1359/jbmr.2001.16.3.429
pmid: 11277259
|
[22] |
Montebugnoli L, Felicetti L, Gissi DB, et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 104(4): 473-477.
doi: 10.1016/j.tripleo.2007.01.008
pmid: 17482847
|
[23] |
Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34)[J]. J Bone Miner Res, 2002, 17(11): 2038-2047.
doi: 10.1359/jbmr.2002.17.11.2038
pmid: 12412812
|
[24] |
Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety[J]. Toxicol Pathol, 2002, 30(3): 312-321.
doi: 10.1080/01926230252929882
pmid: 12051548
|
[25] |
Tashjian AH Jr, Gagel RF. Teriparatide[human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis[J]. J Bone Miner Res, 2006, 21(3): 354-365.
pmid: 16491282
|
[26] |
Hinson AM, Smith CW, Siegel ER, et al. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary[J]. Int J Dent, 2014, 2014: 452737.
|